Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00207792
Status:
UNKNOWN
Last Update Posted:
2007-11-06
First Post:
2005-09-13
Brief Title:
Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Sponsor:
Centre National de Greffe de Moelle Osseuse
Organization:
Centre National de Greffe de Moelle Osseuse
Study Overview
Official Title:
Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Status:
UNKNOWN
Status Verified Date:
2007-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function but whether the effect is strong enough to alter the risk of graft-versus-host disease GvHD is unclear
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor G-CSF Neupogen filgrastim on the risk of acute GvHD after allogeneic bone marrow transplantation
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor G-CSF Neupogen filgrastim on the risk of acute GvHD after allogeneic bone marrow transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None